CHF Solutions, Inc. to Host a Call with Investigator Panel to Discuss Results of a Study Involving Use of Aquadex FlexFlow® ...
September 17 2019 - 8:00AM
CHF Solutions, Inc. (NASDAQ: CHFS) announced today that it will
host a conference call and webcast at 1:00 PM ET on Wednesday,
September 25, 2019 to discuss the results of a multicenter,
retrospective study involving pediatric patients who need kidney
support and utilized the company’s Aquadex FlexFlow system. Stuart
L. Goldstein, M.D. (Cincinnati Children’s Hospital Medical Center),
David Askenazi, M.D. MSPH (Children’s of Alabama), and Shina Menon,
M.D. (Seattle Children’s Hospital), investigators involved in the
study, will provide an overview of the clinical uses and results of
the study. Jeff Cohen, Managing Director, Equity Research,
Healthcare & Medical Technologies at Ladenburg Thalmann &
Co., will be moderating the discussion.
To access the live webcast, please visit the Investors page of
the CHF Solutions website at http://ir.chf-solutions.com or access
the webcast directly at http://ir.chf-solutions.com/events.
Alternatively, you may access the live conference call by dialing
(877) 303-9826 (U.S.) or (224) 357-2194 (international) and using
conference ID: 6985754. An audio archive of the webcast will be
available following the call on the Investor page at
http://ir.chf-solutions.com/events.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company
focused on developing, manufacturing and commercializing the
Aquadex FlexFlow® system for aquapheresis therapy. The Aquadex
FlexFlow system is a clinically proven therapy that provides a
safe, effective and predictable method of removing excess sodium
and fluid from patients suffering from fluid overload. The Aquadex
FlexFlow system is indicated for temporary (up to eight hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy and extended (longer than 8 hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy and require hospitalization. All treatments
must be administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies. The company's vision is to change the
lives of fluid overloaded patients through science, collaboration,
and innovative medical technology. CHF Solutions is a Delaware
corporation headquartered in Minneapolis, Minnesota with wholly
owned subsidiaries in Australia and Ireland. The company has been
listed on the Nasdaq Capital Market since February 2012.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-Or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024